NEW YORK–(BUSINESS WIRE)–Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Mustafa Noor, MD, FACP, has joined the Company as Chief Medical Officer (CMO), following the decision of the current CMO, Dr. Curt Scribner, to step down from his post.
Dr. Noor said: “I think now is the perfect time to join the Olatec team. I see Olatec at a major value inflection point and am thrilled to not only build on the world-class translational science that has been unraveled, but also to help this outstanding team bring dapansutrile to a advanced stage of development and, prospectively, for its approval in the main indications. Dr. Noor continued, “Olatec is at the forefront of a compelling new inflammatory target across multiple disease areas, which creates many opportunities for dapansutrile and OLT-like compounds.
Dr. Charles Dinarello, Scientific Director of Olatec, said: “We are delighted to welcome Dr. Noor to our team. He brings extensive clinical trial expertise and experience as a clinician treating patients to Olatec that will be invaluable in the development of OLT1177.® and its analogues.
Dr. Mustafa Noor’s distinguished career spans over two decades of industry experience. Within large and small pharmaceutical companies, Dr. Noor has contributed to numerous clinical drug development programs, leading and collaborating with teams in the development of novel therapies for inflammation, cardiometabolism, lipid and endocrine disorders. as well as rare diseases. From 2001 to 2006, as Medical Director at Bristol-Myers Squibb, Dr. Noor held positions of increasing responsibility in metabolic, cardiovascular and antiviral programs. From 2006 to 2014 at GSK and Pfizer, he served as Vice President and Clinical Director of GSK’s Center of Excellence in External Drug Discovery and Pfizer’s Therapeutic Innovation Centers, focused on open innovation, research translational and collaboration with biotech and academic partners on a portfolio of early-stage programs in inflammatory disease indications, including inflammatory bowel disease, rheumatoid arthritis, lupus and sarcoidosis. For the past few years, Dr. Noor has been a CMO consultant for emerging companies in the Boston/Cambridge area. Dr. Noor completed his medical training at the University of Chicago and his postgraduate training in endocrinology and metabolism at the University of California, San Francisco. He holds a Master of Science in Clinical Research from Vanderbilt University and is a Board Certified Internal Medicine Specialist in Endocrinology and Metabolism.
Olatec CEO Damaris Skouras said, “This appointment marks an important milestone in the continued development of dapansutrile and our portfolio of OLT Analogue compounds. Given Dr. Noor’s medical and drug development expertise, I am confident that Dr. Noor will make substantial contributions to the strategic direction and oversight of dapansutrile as it progresses towards studies. stage and that our product portfolio of OLT analogues is also progressing. Ms. Skouras continued, “I also express my deepest gratitude to Dr. Scribner whose contributions as CMO during the early stages of clinical development of dapansutrile were significant. While stepping down as CMO, we are excited that Curt will remain on Olatec’s Scientific Advisory Board and continue to support the development of dapansutrile.
Dapansutrile (laboratory code: OLT1177®) is an experimental small molecule, a new chemical entity that specifically binds and blocks NLRP3 (nucleotide binding and oligomerization domain [NOD]‑, leucine-rich repeat, containing a pyrin domain 3), the sensor molecule integrated in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes involved in intracellular surveillance of danger signals that trigger an intense inflammatory response, via the generation of bioactive IL-1β and IL-18 via caspase-1 activation. Dapansutrile has been shown to prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1β and IL-18. NLRP3 is one of the most characterized inflammasome sensors due to its involvement in a wide range of disorders, including sterile inflammation, infections, and rare genetic autoimmune syndromes. Dapansutrile was well tolerated and has been shown to improve clinical outcomes in patients with acute gout flare (see The Lancet Rheumatology) and heart failure (see Journal of Cardiovascular Pharmacology). Dapansutrile has also been observed to have anti-inflammatory properties and other promising activities in a wide range of over 20 preclinical animal models including arthritis, asthma, acute myocardial infarction (AMI) , heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson’s and Alzheimer’s disease.
About Olatec Therapeutics LLC
Olatec is a Phase 2 private biopharmaceutical company developing an oral NLRP3 inhibitor platform to treat and prevent a wide range of acute and chronic inflammatory diseases known to be mediated by IL-1. In addition to the lead compound, dapansutrile, Olatec’s proprietary compound platform includes approximately 60 analogs (OLT analogs) being screened as viable drug candidates. An intellectual property portfolio protecting Olatec’s compounds includes over 130 issued patents, covering dapansutrile and OLT analogs. Olatec’s drug development team is comprised of experienced executives and international experts in translational medicine with unparalleled expertise in inflammation and immunology and has been involved in the discovery and development of first-line treatments against inflammation on the market today. For more information, please visit http://www.olatec.com.
Disclaimer and Forward-Looking Statement
The information contained in this document is provided for informational purposes only. The Company makes no express or implied representations or warranties as to the completeness of this information. All forward-looking statements contained in this press release are based on assumptions made by Olatec at the time of the preparation of this press release. Any forward-looking statements contained in this press release are subject to known and unknown risks, uncertainties and other factors that may differ materially from those contemplated in such forward-looking statements. All information regarding industry data has been obtained from sources believed to be reliable and up-to-date, but the accuracy thereof cannot be guaranteed by the Company. Olatec undertakes no obligation to update or revise any forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of the preparation of this press release, or to reflect the occurrence of unforeseen events. .